3/22
02:32 pm
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
3/22
01:50 pm
cldx
Rating for CLDX
Low
Report
Rating for CLDX
2/27
12:03 pm
cldx
Rating for CLDX
Low
Report
Rating for CLDX
2/27
12:03 pm
cldx
Rating for CLDX
Low
Report
Rating for CLDX